Top Markets
Coin of the day
Enimmune corporation Enimmune corporation

Enimmune corporation

6564
Rang in Aktien #26781
Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused... Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused on the research, development, and commercialization of pharmaceutical products. Among its key offerings is Tuberculin PPD RT23 SSI, an approved diagnostic agent utilized in tuberculin tests to ascertain the presence of tuberculosis infection in patients. Beyond its existing products, Enimmune is heavily invested in developing vaccines aimed at combating a diverse array of infectious diseases. These include, but are not limited to, vaccines for enterovirus, pneumonia, norovirus, dengue fever, and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Established in 2014, the company maintains its headquarters in Taichung City, Taiwan.
Aktienkurs
$0.52468396
Marktkapitalisierung
$37.85M
Veränderung (1 Tag)
1.23%
Veränderung (1 Jahr)
-4.53%
Land
TW
Handel Enimmune corporation (6564)

Kategorie

Dividendenrendite-Verlauf für Enimmune corporation (6564)
Dividendenrendite (TTM) von Enimmune corporation (Aktienkürzel: 6564) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Enimmune corporation (6564) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH